Project Grant R44CA298774
Award Date 8/12/25
Completion Date 7/31/27
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Delaware, USA
Similar Awards
- This $1,125,000 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and clinical testing of an "Ultra-Fast Manufactured CAR-T Therapy" by Kure Ai Inc. The key objectives are to: Validate an automated, closed system manufacturing process for the "UF-KURE19" CAR-T product through a Phase 1b clinical trial. Extend the safety and efficacy data for this rapidly manufactured CAR-T therapy in patients with...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,031,566 to Mucommune LLC to develop in vivo-engineered B7-H3 chimeric antigen receptor (CAR) T-cells for ovarian cancer therapy. The project aims to leverage a novel viral vector system to directly engineer circulating T-cells in the body, rather than harvesting, modifying, and expanding them ex vivo. This approach has the potential to reduce the time and cost of CAR-T therapy...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,625.00 to Cellchorus Inc., a Houston-based company specializing in advanced cell analysis technologies, to develop a high-throughput platform for profiling the functional signatures of CAR T cells from patients with relapsed/refractory large B cell lymphoma (r/r LBCL). The goal is to create a scalable, AI-powered imaging technology called Time-lapse Imaging Microscopy in...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Aerocytek, Inc. to develop an innovative approach for point-of-care autologous CAR-T cell manufacturing. The project aims to overcome current challenges in large-scale production and integration of CAR-T cell therapies by leveraging targeted microbubble-based technologies for T cell selection, activation, and transduction. This solution seeks to democratize the...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- This $314,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of Persistence Therapeutics, Inc.'s novel "SynthNode" approach for CAR T cell therapy. The SynthNode is an implantable device the size of a dime that mimics the function of a lymph node, producing potent, antigen-specific CAR T cells that persist long-term for improved patient outcomes. This fast-track Phase I/II project will complete prototyping,...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- The National Cancer Institute (NCI) awarded Lifengine Animal Health Laboratories Incorporated a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The award period runs from August 4, 2025 to July 31, 2026. The grant funds the development of chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion by overexpressing the C-MYB transcription factor. This research aims to improve the therapeutic efficacy and duration of...